Dialysis hyperphosphatemia therapeutics market seen reaching $7.34B by 2030

The dialysis hyperphosphatemia therapeutics market is projected to grow from $4.95 billion in 2026 to $7.34 billion by 2030, driven by rising chronic kidney disease cases and broader dialysis use. The outlook underscores growing demand for phosphate-control treatments that can reduce complications for patients with kidney failure.

Why it matters: - Dialysis hyperphosphatemia therapeutics help control elevated phosphate levels in dialysis patients with chronic kidney disease or kidney failure. - Managing phosphate is tied to fewer bone disorders, lower cardiovascular risk, and better quality of life. - The market’s expected growth signals expanding demand for renal care treatments as kidney disease cases rise worldwide.

What happened: - The Business Research Company published The Dialysis Hyperphosphatemia Therapeutics Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Sept. 28, 2026. - The report estimates the market will rise from $4.47 billion in 2025 to $4.95 billion in 2026. - The market is projected to reach $7.34 billion by 2030, expanding at a 10.3% CAGR during the forecast period. - North America held the largest market share in 2025. - Asia-Pacific is expected to grow the fastest over the next several years.

The details: - Market growth is being driven by rising chronic kidney disease cases, a larger global dialysis population, stronger awareness of phosphate-management complications, wider use of phosphate binder drugs, and better healthcare infrastructure for renal care. - Forecast-period growth is expected to come from first-in-class phosphate control therapies, more tailored renal disease management, combination therapy strategies, home dialysis adoption, and higher investment in kidney disease research. - The report highlights trends including more advanced phosphate binder medications, personalized hyperphosphatemia treatment, better adherence to oral therapies, new phosphate-regulation mechanisms, and safer dialysis support options. - Dialysis hyperphosphatemia therapeutics are designed to reduce phosphate buildup in the bloodstream during dialysis. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The 2026 report includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics, and updated graphics and tables. - A free sample report is available. - The full market report is also available online.

Between the lines: - The market forecast points to a broader shift toward chronic disease management rather than one-time treatment. - Home dialysis adoption and personalized treatment strategies suggest providers are looking for therapies that fit more varied care settings and patient needs. - The growth outlook also reflects the commercial importance of therapies that can improve adherence, since phosphate control often requires ongoing medication use. - Kidney Research UK reported in June 2023 that about 7.19 million people in the UK were living with chronic kidney disease, more than 10% of the population. - Kidney Research UK expects that figure to rise to 7.61 million by 2033.

What's next: - Drug developers and renal-care companies are likely to keep targeting better phosphate-control therapies and combination approaches. - The Asia-Pacific region may draw more attention from manufacturers and investors as the fastest-growing market. - Continued growth in chronic kidney disease cases could keep pushing demand for dialysis-support therapies through the end of the decade.

The bottom line: - Dialysis hyperphosphatemia therapeutics are moving from a niche renal-care category to a larger, fast-growing global market tied to the expanding burden of kidney disease.